Form 4: Relmada Therapeutics CFO Buys Shares
Insider Transaction (Form 4)
Maged Shenouda, Chief Financial Officer of Relmada Therapeutics, Inc., purchased 200,000 shares of common stock on September 9, 2026.
Summary
- Open-market purchase: acquired 120,200 Common Stock at $4.20 ($504,840) on September 9, 2026; holds 920,200 after (Direct).
- Open-market purchase: acquired 79,800 Common Stock at $4.25 ($339,150) on September 10, 2026; holds 1,000,000 after (Direct).
Sentiment
Score: 8
Explanation: StockSavvy.ai views this as a bullish signal: an insider made an open-market purchase of $843,990, committing personal capital to the stock.
Insider Transactions
Maged Shenouda — Officer (Chief Financial Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-09 | Open-market purchase | Common Stock | 120,200 | $4 | $504.8K | 920,200 |
| 2026-09-10 | Open-market purchase | Common Stock | 79,800 | $4 | $339.1K | 1,000,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-09 | Open-market purchase (120,200 shares) |
| 2026-09-10 | Open-market purchase (79,800 shares) |
Keywords
insider transaction, Form 4, RLMD, RELMADA THERAPEUTICS, INC., bullish, Maged Shenouda
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.